A new technique helps researchers single out and characterize toxic aggregates of TDP-43 from human brain.
Multiplexed marker analysis in single cells from human brain corroborates expression data, identifies microglia subsets in human brain.
Studies in mice and humans show that sleep suppresses extracellular tau and slows its spread.
Neural progenitor cells derived from people with sporadic AD are missing the transcriptional repressor REST in the nucleus. This lets neurogenesis run wild, exhausting a person’s stem cell pool.
In cognitively normal people, a set of blood proteins may predict whether or not amyloid plaques have deposited in a person’s brain.
The approach provides an in vitro system that more closely resembles the brain milieu than do cell cultures, and can be used to model other proteinopathies as well.
Knocking down or blocking the CCR5 receptor with an HIV drug improved motor symptoms and learning and memory in a mouse model of stroke. Recently, researchers in China knocked out this gene in babies using CRISPR.
Only 16 percent of seniors report being assessed for cognition during yearly checkups. Eighty-two percent think it should be routine.
In people at intermediate risk for cardiovascular disease, the meds had no effect on cognitive decline over six years.
Among British civil servants, the quality of their diet did not correlate with their risk of developing dementia cognitive decline over 25 years.
A prospective progeria drug revs up cellular autophagy and clears tau in neurons derived from patients with frontotemporal dementia. In mouse models, the drug rescues abnormal behavior.
The method purportedly distinguishes patients from controls with more than 90 percent sensitivity and specificity.
Senolytic drugs kill these cells, temper Aβ, and improve cognition in transgenic mice.
In people carrying two mutated copies of the trophic receptor, important brain structures, such as the corpus callosum, never developed.
Inhibiting the receptor activates microglia to mop up debris, making CD33 an attractive therapeutic target.